Inhibitor selectivity of CNTs and ENTs.

Area of Science:

• Pharmacology
• Molecular Biology
• Drug Discovery

Background:

• Concentrative nucleoside transporters (CNTs; SLC28) and equilibrative nucleoside transporters (ENTs; SLC29) are crucial drug targets.
• These transporters can also contribute to drug toxicity and adverse events.
• Understanding inhibitor selectivity is key for developing safer and more effective therapeutics.

Purpose of the Study:

• To investigate the role of base and monosaccharide moieties in the selectivity of nucleoside transporter inhibitors.
• To compare the inhibitor profiles of CNTs and ENTs.
• To identify differences in inhibitor selectivity within the CNT family.

Main Methods:

• Screening of compounds with arabinose or cytosine moieties against CNT and ENT transporters.
• Analysis of IC50 values to determine inhibitor potency and selectivity.
• Correlation analysis of inhibitor activity across different transporter subtypes.

Main Results:

• Compounds with a cytosine moiety showed higher potency against CNTs compared to arabinose-containing compounds.
• ENTs demonstrated a preference for compounds with an arabinose moiety.
• Significant differences in inhibitor selectivity were observed between CNT and ENT families, and within CNT subtypes (CNT1, CNT2, CNT3).
• Nelarabine was the only compound showing selectivity between ENT1 and ENT2.

Conclusions:

• Inhibitor selectivity for nucleoside transporters is influenced by the chemical structure of the inhibitor, specifically the base and monosaccharide components.
• CNTs and ENTs exhibit distinct preferences for different inhibitor types.
• Further research into transporter-family-specific inhibitor design is warranted to optimize therapeutic outcomes and minimize adverse effects.